ANAB logo

AnaptysBio, Inc. Common Stock

ANAB

ANAB: AnaptysBio Inc is a clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonists. The entity generates revenue from collaborative research and development arrangements.

more

Show ANAB Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of ANAB by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ANAB's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) Jun. 07, 2022
  • Patent Title: Antibodies directed against programmed death-1 (pd-1) Oct. 26, 2021
  • Patent Title: Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (il-36r) Sep. 28, 2021
  • Patent Title: Antibodies directed against lymphocyte activation gene 3 (lag-3) Nov. 17, 2020
  • Patent Title: Method of treating inflammatory disorder with antibodies directed against interleukin-33 (il-33) Nov. 17, 2020
  • Patent Title: Antibodies directed against programmed death-1 (pd-1) Aug. 11, 2020
  • Patent Title: Antibodies directed against interleukin 36 receptor (il-36r) Jan. 07, 2020
  • Patent Title: Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) Dec. 17, 2019
  • Patent Title: Antibodies directed against interleukin-33 (il-33) and methods of making and using Aug. 28, 2018
  • Patent Title: Antibodies directed against nerve growth factor (ngf) Apr. 24, 2018
  • Patent Title: Antibodies directed against programmed death-1 (pd-1) Nov. 14, 2017
  • Patent Title: Methods of generating libraries and uses thereof May. 02, 2017
  • Patent Title: Antibodies directed against il-17 May. 03, 2016
  • Patent Title: Methods of generating libraries and uses thereof Feb. 16, 2016
  • Patent Title: Humanized antibodies directed against complement protein c5 Sep. 15, 2015
  • Patent Title: Antibodies directed against nerve growth factor (ngf) Jan. 06, 2015
  • Patent Title: Methods of generating libraries and uses thereof Apr. 01, 2014
  • Patent Title: Methods of generating libraries and uses thereof Dec. 10, 2013
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ANAB in WallStreetBets Daily Discussion

ANAB News

Recent insights relating to ANAB

CNBC Recommendations

Recent picks made for ANAB stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ANAB

Corporate Flights

Flights by private jets registered to ANAB